SEC Filing Summary: AspenBio Pharma, Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by AspenBio Pharma, Inc. on February 15, 2006. The registrant is incorporated in Colorado and is headquartered in Castle Rock, CO. The filing serves to disclose recent developments regarding the company's Human Appendicitis Test.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a specific event and does not contain financial statements or pro forma financial information.
Material Changes
The material change reported is the issuance of a press release titled "AspenBio Pharma Announces Recent Developments Regarding Human Appendicitis Test." No quantitative financial changes versus prior periods are detailed in this document.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) containing details on the appendicitis test developments. The document itself does not contain specific management commentary, forward-looking guidance, risk factors, or contingencies beyond the reference to the attached exhibit.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific details on the Human Appendicitis Test developments.
- Verify the current status of the appendicitis test clinical trials or regulatory approvals.
- Check subsequent filings for any financial impact resulting from the developments announced on February 15, 2006.
- Confirm the company's cash position and runway, as this filing does not provide liquidity data.